REG - BSF Enterprise PLC - 3D Bio-Tissues Product Partnership Progress

BSF EnterpriseAnnouncement

24/11/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231124:nRSX5345Ua&default-theme=true

RNS Number : 5345U  BSF Enterprise PLC  24 November 2023

24 November 2023

BSF Enterprise PLC

("BSF" or the "Company")

 

3D Bio-Tissues Product Partnership Progress

 

BSF (LSE: BSFA), (OTCQB: BSFAF), the Main Market listed biotech company and
owner of pioneering UK-based clinical and cellular agriculture company 3D
Bio-Tissues (3DBT), provides an update on the Company's partnership progress
across several of 3DBT's product verticals.

Etsyl™ Commercial Update

3DBT is pleased to announce that it has entered into a proof-of-concept
contractual agreement with one of the largest cosmetic companies in the world,
which will test the suitability of the Company's proprietary lipopeptide
product, Etsyl™, for use within its skin cream cosmetic solutions.

3DBT is harnessing the natural regenerative ability of human skin cells to
drive rapid tissue regeneration and repair. Its Etsyl™ promotes cellular
collagen production in human skin cells, with cosmetic and pharmacological
applications as a bioactive ingredient in skincare formulations for the
fabrication of native-like skin substitutes for clinical, cosmetic and
industrial applications.

The cosmetic company which BSF is working with specialises in the research and
development of bioactive ingredients for skin care which, with proven
efficacy, can aid in anti-ageing, moisturising and acne control.

EIT Grant

In September 2023, 3D Bio-Tissues announced that it has been awarded a
EUR612,000 grant from the European Institute of Innovation and Technology
("EIT Food") to upscale the production and sales of its proprietary serum-free
media, City-Mix™. City-Mix™ is an animal-free cell growth agent for
culturing skin, muscle and fat cells for use in cultivated meat and leather
production.

Further to this, 3DBT is pleased to announce that it now has two new staff
members in place to focus on securing additional procurement, manufacturing
and distribution partnerships in the food-tech and biotech sectors, including
Mr Adam Crosby, an operational manager with broad-level experience across
multiple industries, and a successful track record in delivering
multi-million-pound projects and facilitating growth. The Company has also
hired an experienced Technical Sales Specialist to strengthen its sales team.

Book launch

Chief Executive of 3DBT, Professor Che Connon, has co-authored a book entitled
Advances in Cultured Meat Technology, that explores the potential of cultured
meat production in solving food security. Publication of the book is expected
to further enhance Professor Connon, and the Company's international profile
and reputation within the rapidly advancing cultured meat industry.

Che Connon, Chief Executive of 3DBT and Managing Director of BSF said: "We
are delighted to be working with one of the world's largest cosmetic
companies, which highlights the potential of our Etsyl product and the diverse
applications of our technology. Furthermore, with an enlarged team in hand, we
hope to secure further partnerships and sales for our various product
offerings at an accelerated pace, and we look to the future with
confidence."

 

For further enquiries, please visit www.bsfenterprise.com
(http://www.bsfenterprise.com/)  or contact:

 BSF Enterprise PLC                       Via SEC Newgate below
 Geoff Baker - Executive Director

 Che Connon - CEO & Director

 Shard Capital (Broker)
 Damon Heath                              0207 186 9000

 Isabella Pierre                          0207 186 9927

 SEC Newgate (Financial Communications)
 Bob Huxford                              020 3757 6882

 Elisabeth Cowell                         BSF@secnewgate.co.uk

 George Esmond

 

ISIN of the Ordinary Shares is GB00BHNBDQ51

SEDOL Code is BHNBDQ5.

 

Notes to Editors

BSF Enterprise PLC (BSF) is focused on unlocking the next generation of
biotechnological solutions - using cell-based tissue engineering to help
generate cultured meat, lab-grown leather, as well as human corneas, collagen
growth and skin substitutes, as part of a radical transformation to deliver
sustainable solutions across a variety of sectors.

It owns 100% of 3D Bio-Tissues (3DBT), a tissue engineering with
patent-protected IP that is already producing human corneas to help restore
vision to millions of people and successfully produced the UK's first
high-quality lab-grown meat from its laboratory in Newcastle in 2023.

BSF aims to deliver growth to shareholders through the continued
commercialisation of 3DBT's IP, which has multiple applications, as well as
through M&A. It aims to acquire a suite of technologies that underpins the
development of tissue templating for corneas, meat and leather, and license
out the IP to manufacturers, wholesalers and distributors to help manufacture
the products at scale.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCNKNBQNBDBODB